返回 
加入收藏
奥马珠单抗治疗重度过敏性哮喘的药物经济学评价
x
请在关注微信后，向客服人员索取文件
| 篇名： | 奥马珠单抗治疗重度过敏性哮喘的药物经济学评价 |
| TITLE： | Pharmacoeconomic evaluation of omalizumab in the treatment of severe allergic asthma |
| 摘要： | 目的 从我国医疗提供者角度出发，对奥马珠单抗治疗重度过敏性哮喘的经济性进行评价。方法基于一项奥马珠单抗治疗重度过敏性哮喘的国际多中心研究数据，根据重度过敏性哮喘的疾病发展进程建立Markov模型，循环周期为4周，以质量调整生命年（QALYs）和增量成本-效果比（ICER）为产出指标，模拟奥马珠单抗联合标准治疗（SoC）方案对比SoC方案治疗重度过敏性哮喘的长期健康效果与成本，并采用单因素敏感性分析、概率敏感性分析和情境分析检验结果的稳健性。结果与SoC方案相比，奥马珠单抗联合SoC方案的ICER为107723.05元/QALY，小于3倍2023年我国人均国内生产总值（GDP）的意愿支付（WTP）阈值（268074元/QALY）。单因素敏感性分析结果显示，基线血清总免疫球蛋白E水平对模型的稳健性影响最大。概率敏感性分析结果显示，在阈值为268074元/QALY时，奥马珠单抗+SoC方案具有经济性的概率为93.00%。情境分析结果显示，真实世界中奥马珠单抗按药品规格而不按实际用量的计费方式可能会升高ICER。结论以3倍2023年我国人均GDP为WTP阈值时，与SoC方案相比，奥马珠单抗联合SoC方案治疗重度过敏性哮喘具有经济性。 |
| ABSTRACT： | OBJECTIVE To evaluate the cost-effectiveness of omalizumab in the treatment of severe allergic asthma from the perspective of healthcare providers in China. METHODS Based on the data from an international multicenter study of omalizumab in the treatment of severe allergic asthma， the Markov model was constructed according to the progression of severe allergic asthma， with a cycle of 4 weeks. Long-term health outcomes and costs of omalizumab combined with standard of care（SoC） regimen versus SoC regimen in the treatment of severe allergic asthma were simulated by using quality-adjusted life years （QALYs） and incremental cost-effectiveness ratio（ICER） as output indexes. One-way sensitivity analysis， probabilistic sensitivity analysis， and scenario analysis were performed to test the robustness of the results. RESULTS Compared with the SoC regimen， ICER for the omalizumab combined with SoC regimen was 107 723.05 yuan/QALY， which was less than the willingness-to-pay（WTP） threshold （268 074 yuan/QALY） calculated by three times per capita gross domestic product（GDP） in China in 2023. The one-way sensitivity analysis showed that the baseline serum level of immunoglobulin E had the greatest impact on the robustness of the model. The probabilistic sensitivity analysis showed that the omalizumab+SoC regimen had a 93.00% probability of being cost- effective. The scenario analysis showed that in the real world， the billing method of omalizumab based on specifications rather than actual usage may increase ICER. CONCLUSIONS Compared with the SoC regimen， the combination of omalizumab and SoC regimen for treating severe allergic asthma is cost-effective， with a WTP threshold of three times China’s per capita GDP |
| 期刊： | 2024年第35卷第10期 |
| 作者： | 熊朝刚；朱玉蓉；安梦娜；李颖；张鑫；章圣洁；冯柯臻；封卫毅 |
| AUTHORS： | XIONG Chaogang， ZHU Yurong，AN Mengna，LI Ying，ZHANG Xin，ZHANG Shengjie，FENG Kezhen，FENG Weiyi |
| 关键字： | 奥马珠单抗；重度过敏性哮喘；成本-效用；Markov模型；药物经济学 |
| KEYWORDS： | omalizumab； severe allergic asthma； cost- |
| 阅读数： | 43 次 |
| 本月下载数： | 4 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
